Receptor Theory & Toxicant-Receptor Interactions Richard B. Mailman.

Slides:



Advertisements
Similar presentations
LAKSHMAN KARALLIEDDE OCTOBER 2011
Advertisements

Drug Chemistry and Toxicology CHE 618 Alexander Nazarenko.
DRUG-RECEPTOR INTERACTIONS
Protein Binding Phenomena Lecture 7, Medical Biochemstry.
Cooperative Site Binding (11.8) Binding of ligands to a biomolecule can affect the ability of other active sites to bind ligands and is called cooperative.
Protein Structure/Function C483 Spring Proteins segments which fold first can promote the folding of other sections of the protein into the native.
Drug ? RESPONSE altering their biochemical &/or biophysical activity  Depress  Activate  Replace  Irritate  Destroy PHARMACODYNAMICS  Absorb 
Chapter 2 Chemical Foundations.
Pharmacodynamics Chapter 2. Concentration/Response Relationship Can meas drug/ receptor binding directly –Ex: Radioimmunoassay Ex: radioactive drug binding.
Pharmacology-1 PHL 313 Fourth Lecture By Abdelkader Ashour, Ph.D. Phone:
Drug-Receptor Interactions Pharmacodynamics
RESPONSE To alter their biochemical &/or biophysical activity  Depress  Activate  Replace  Irritate  Destroy PHARMACODYNAMICS  Absorb  Distribute.
RESPONSE To alter their biochemical &/or biophysical activity  Depress  Activate  Replace  Irritate  Destroy PHARMACODYNAMICS  Absorb  Distribute.
Farmakologi Molecular - Reseptor
Principles of Pharmacology: Pharmacodynamics
Binding Equilibria (11.6) Binding of ligands to proteins is prevalent in biochemistry – Catalytic behavior of proteins can be described through binding.
DRUG RECEPTOR INTERACTIONS
Principles of Pharmacology: Pharmacodynamics
Quantifying the drug-target binding affinity. Receptors as targets (Receptors are 45% of current drug targets) Receptors are areas of proteins found in.
Dr. Steven I. Dworkin Pharmacology for the Health Sciences Lecture 2a.
PHC 222 Part(I) Dr. Huda Al Salem Lecture (7). Factors that affect the efficacy 2- Concentration-Response Curves: Agonist Antagonist Partial agonist Desensetization.
PHC 222 Medicinal Chemistry-1- Part(I) Dr. Huda Al Salem Lecture (1)
Receptors - Quantitation Quantitation of Receptor Occupation and Response for School of Biomedical Engineering, Drexel University Prof. Philip Lazarovici,
 Receptors are mostly membrane-bound proteins that selectively bind small molecules called ligands which results in physiological response.  They are.
Pharmacology UG-Course Touqeer Ahmed PhD 19 th February, 2015 Atta-ur-Rahman School of Applied Biosciences National University of Sciences and Technology.
Biol 304 Week 3 Equilibrium Binding Multiple Multiple Binding Sites.
1 In the name of GOD. 2 Zeinab Mokhtari 06-Jan-2010.
BASIC PHARMACOLOGY 2 SAMUEL AGUAZIM(MD).
RESPONSE altering their biochemical &/or biophysical activity  Depress  Activate  Replace  Irritate  Destroy PHARMACODYNAMICS  Absorb  Distribute.
HuBio 543 September 6, 2007 Frank F. Vincenzi
How drugs Act :General principles Lecture 2
Year One Pharmacodynamics
PHARMACODYNAMICS M.T. Piascik PHA 824 November 11, 2008.
At the end of this lecture, the students will be able to: 1.Define receptors 2.Define agonists 3.List types of agonists 4. Define antagonists 5. List.
Dr. Laila M. Matalqah Ph.D. Pharmacology Pharmacodynamics 1 General Pharmacology M212.
RESPONSE To alter their biochemical &/or biophysical activity  Depress  Activate  Replace  Irritate  Destroy PHARMACODYNAMICS  Absorb  Distribute.
Dr. Laila M. Matalqah Ph.D. Pharmacology Pharmacodynamics 2 General Pharmacology M212.
Clinical Pharmacokinetics. Time course Duration Onset Absorptive phase Elimination phase.
Prof. hanan Hagar.  Identify different targets of drug action Ilos Elaborate on drug binding to receptors Differentiate between their patterns of action;
Pharmacodynamics. Pharmacodynamics  The study of the biochemical and physiologic effects of drugs and the molecular mechanisms by which those effects.
DRUG RECEPTORS AND PHARMACODYNAMICS
Pharmacodynamics What the drug does to the body?
Pharmacodynamics Collected and Prepared By S.Bohlooli, PhD.
Pharmacodynamics. * The study of the biochemical and physiologic effects of drugs and the molecular mechanisms by which those effects are produced * The.
Affinity and Avidity by: Omar Ammar
Receptor Theory & Toxicant-Receptor Interactions
PHL 210 Pharmacology Second Lecture By Abdelkader Ashour, Ph.D. Phone:
Understanding the Basics of Pharmacology
Drug-Receptor Binding and Receptor Types
Tissue response compared to receptor occupation
Pharmacodynamics.
5 Pharmacodynamics.
Chapter 6 CHM 341 Fall 2016 Suroviec.
Drug-Receptor Interactions
Parameters to be calculated
INTRODUCTION to Pharmacology
Pharmacodynamics 2.
Pharmacology UG-Course
Drug-Receptor Interactions
Pharmacology UG-Course
Receptive substances proposed 1909 by Langley (nicotine)
Pharmacodynamic Dr. Hashem Mansour.
Introduction to Pharmacology
Lee E Limbird, Palmer Taylor  Cell 
Information needed for calculations
Pharmacodynamics i Prof. hanan Hagar.
Introduction to Pharmacology
Drug-Receptor Interactions
Drug- Receptor Interaction
Full agonists The “agonists” referred to so far are FULL AGONISTS
Presentation transcript:

Receptor Theory & Toxicant-Receptor Interactions Richard B. Mailman

Some examples of receptors 1 E 2 R E 1 ligand       2 Ion R R ligand nucleus R R 3 ligand E R R 4 R R ATP ADP P ATP ADP P P P

What is a receptor? To a neuroscientist –A protein that binds a neurotransmitter/modulator To a cell biologist or biochemist –A protein that binds a small molecule –A protein that binds another protein –A nucleic acid that binds a protein To a toxicologist –A macromolecule that binds a toxicant Etc.

Definitions Affinity: –the “tenacity” by which a ligand binds to its receptor Intrinsic activity (= “efficacy”): –the relative maximal response caused by a drug in a tissue preparation. A full agonist causes a maximal effect equal to that of the endogenous ligand (or sometimes another reference compound if the endogenous ligand is not known); a partial agonist causes less than a maximal response. –Intrinsic efficacy (outmoded): the property of how a ligand causes biological responses via a single receptor (hence a property of a drug). Potency: –how much of a ligand is needed to cause a measured change (usually functional).

Radioactivity Principles Specific activity depends on half-life, and is totally independent of mode or energy of decay. When decay occurs for all of the biologically important isotopes ( 14 C; 3 H; 32 P; 35 S; 125 I; etc.), the decay event changes the chemical identity of the decaying atom, and in the process, destroys the molecule on which the atom resided. –e.g., 3 H  He –Do NOT adjust the specific activity of your radiochemical based on decay – for every decay, there is a loss of the parent molecule.

Drug-Receptor Interactions Ligand + Receptor Lgand-Receptor Complex Response(s)

Bimolecular Interactions: Foundation of Most Studies Rearrange that equation to define the equilibrium dissociation constant K D. At equilibrium: Ligand + Receptor Ligand-Receptor Complex Response(s)

Saturation Equations

Linear & Semilog Free Linear Plot Bound log [Free] Semi-Log Plot Bound

Radioreceptor Assay (Simple) unbound labeled drug + unbound test drug drug-receptor complex radiolabeled drugreceptor preparationtest drug Filtration Beta Counter Tissue Preparation

Characterizing Drug-Receptor Interactions: Saturation curves Radioligand Added (cpm x 1000) Amount Bound Specific Binding! (calculated) Non-Specific Total Binding

Scatchard plot Specific Binding Specific Binding/ Free Radioligand B max -1/K D

Competition Curve log [ligand] (nM) Total Binding (dpm *10, e.g.) IC50 Top Bottom Specific Binding NSB

Calculations from Basic Theory (I) log [competing ligand] (M) Specific Binding (%) % 10% 81 Fold

Calculations from Basic Theory (II) log [competing ligand] (M) Specific Binding (%) % 9% 100-fold Commit this to memory!!!!!

Competition Curves Log [ligand] (nM) Specific Binding (%) B A

Concentration (nM) Specific Binding (%) ADCB

Functional effects & antagonists Log Agonist Concentration (M) Response (Fraction of maximal) Control (agonist with no antagonist) + Increasing concentrations of antagonist B Raw Data

Spare receptors and “full agonists”  D1D1 E1E1   E2E2  R E1E1   cAMP stimulation ???? D1D1 D1D1

Full & Partial Agonists Concentration (nM) Full agonist Partial agonist (% stimulation relative to dopamine) cAMP synthesis